ASX Release

Clinical Trial Updates

Melbourne, Australia (29 January 2018): Clinical-stage oncology company Prescient Therapeutics Limited (ASX: PTX; Prescient) is delighted to provide an update on its clinical trials following removal of all clinical holds on its PTX-200 clinical trials.

Prescient's CEO and Managing Director, Steven Yatomi-Clarke said, "The clinical holds naturally caused a delay in recruitment and required us to focus resources to address the holds. Pleasingly, these were met successfully and in a relatively timely manner. Fortunately, at the time of the clinical holds, Prescient was under budget and either ahead of schedule or on schedule in each of our trials. Accordingly, Prescient is well placed to minimize delays. 2018 is shaping up to be a year with many clinical milestones, which is exciting for shareholders."

PTX-200

All PTX-200 trials are now off clinical hold and are either currently recruiting or in the process of obtaining requisite institutional-level approvals to recommence recruitment.

Prescient is currently undertaking another manufacturing run of PTX-200 to meet increased clinical needs.

HER2-negative breast cancer

An important near-term milestone is the release of the final Phase 1b results of PTX-200 with paclitaxel in locally advanced and metastatic HER2-negative breast cancer. Final results from the Phase 1b trial are expected Q1 2018.

The clinical hold was lifted without amendment to the dosing schedule, meaning that this trial can effectively recommence from where it stopped. The trial is currently in Phase 2, with 5 patients qualifying for Phase 2 data analysis.

Based on final Phase 1b results, Prescient will take the opportunity to modify the protocol with a view to strengthening Phase 2 analysis; in particular, stratifying patients based on their hormone receptor status to observe responses in these different breast cancer sub-types. Recruitment for Phase 2 will then recommence under this revised design, expected around the middle of 2018.

Acute Myeloid Leukemia (AML)

Recruitment in the trial of PTX-200 with cytarabine in relapsed or refractory AML has recommenced following the removal of the clinical hold. A total of five patients have now been recruited to the second dosing cohort of 35mg/m^2.

Participating clinicians are pleased with the progress of the trial. The Phase 1b component is on track to complete recruitment around mid-2018 (although it may take slightly longer if the trial achieves the highest dose escalation of PTX-200).

Ovarian Cancer

Following lifting of the hold of the trial of PTX-200 and carboplatin in platinum-resistant recurrent ovarian cancer, Prescient has taken the opportunity to make further amendments to the protocol (that are unrelated to PTX-200) to aid flexibility in carboplatin dosing. This has been submitted for FDA and internal review board approval to allow recommencement of recruitment.

Prescient has now treated six patients at the second dosing cohort of 25mg/m^2 and twelve patients in total. Prescient is aiming to complete this Phase 1b trial by the end of 2018.

PTX-100

Preparations for the pilot study are underway. PTX-100 has previously completed a Phase 1 study in solid tumors, which demonstrated safety, tolerability and stable disease in some patients with advanced cancers. This next trial plans to understand pharmacokinetics and pharmacodynamics, particularly in the hematological setting, and correlating this against Rho and Ras mutant status of patients and if successful, will potentially enable further trials in RhoA mutant cancers. This trial is planned to commence mid-year.

The ultimate goal of this program, should the trials be successful, is to progress towards a registration study in mutant RhoA lymphomas.

Manufacturing PTX-100 is underway and scheduled to coincide with this the timeline. By utilizing existing starting product, Prescient has avoided the costs of a very expensive manufacturing run for this pilot study.

ENDS

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing targeted therapies that address specific mutations that drive cancer and contribute to resistance.

Prescient's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials. The first is a Phase 1b/2 trial evaluating PTX-200 as a new therapy for relapsed and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt); Yale Cancer Center in New Haven, Connecticut (Yale) and Kansas University Medical Center (KUMC) under the leadership of Professor Jeffrey Lancet, MD.

Prescient is also conducting a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase 1b/2 trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

Prescient's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It inhibits the activation of Rho, Rac and Rho circuits in cancer cells, which act as key oncogenic pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors and will be the focus of studies in rare hematological malignancies, namely RhoA mutant lymphomas.

Further enquiries:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics Limited
+61 417 601 440

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not

be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.